Pharmafile Logo

Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market

Published in eyeforpharma February 2016 by Rachel Howard


How large is the opportunity for pharma and healthcare companies in Taiwan?

In our latest article for eyeforpharma we explore Taiwan’s healthcare system, and look at the broader economic and demographic factors which need to be addressed when considering the opportunity for pharma and healthcare companies in Taiwan.

Find out more:
http://bit.ly/1UadDJA


This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Free Thinking: Behavioural economics

Our Free Thinking white paper asks, does behavioural economic theory have a role to play in pharmaceutical market research?

Article: The Colombia Conundrum

Published in eye for pharma 30 January by Marc Yates

Ageing in China: The Implications for Healthcare

Published in eye for pharma 12 December by Marc Yates

Exploring MINT: Part 4 – Turkey

In the fourth and final of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in...

Getting to grips with Russia’s healthcare market

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Exploring MINT: Part 3 – Nigeria

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

Exploring MINT: Part 2 – Indonesia

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Free Thinking: Leveraging the ASEAN Market

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.